Source: Health Products and Food Branch (CA) Revision Year: 2020 Publisher: sanofi-aventis Canada Inc., 2905 Place Louis-R.-Renaud, Laval, Quebec, H7V 0A3
ZAROXOLYN (Metolazone Tablets, USP).
| Pharmaceutical Form |
|---|
|
Tablets. ZAROXOLYN (metolazone) 2.5 mg is available as a pink, slightly biconvex tablet, debossed with its numeric strength on one side and “ZAROXOLYN” on the other and contains 2.5 mg metolazone. |
ZAROXOLYN 2.5 mg tablets contain 2.5 mg of the active ingredient metolazone.
Chemical name: 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
Molecular Formula: C16H16ClN3O3S
Molecular Weight: 365.83
Description: white to off-white crystalline powder
Solubility: in water (gm/mL): 2.4 × 10-5, 25°C in 95% ethanol (gm/mL): 9 × 10-3, 25°C in serum (gm/mL): 4.2 × 10-5, 37°C
pKa: 9.7
Melting Point: 253-259°C
| Active Ingredient | Description | |
|---|---|---|
| Metolazone |
Metolazone is a diuretic antihypertensive drug for the treatment of edema. Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. |
| List of Excipients |
|---|
|
Non-medicinal ingredients: D&C Red #33 aluminum lake Alcohol-, gluten-, lactose-, paraben-, sucrose- and tartrazine- free. |
sanofi-aventis Canada Inc., 2905 Place Louis-R.-Renaud, Laval, Quebec, H7V 0A3
Submission Control No.: 211229
| Drug | Countries | |
|---|---|---|
| ZAROXOLYN | Canada, Estonia |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
